Janus Kinase Inhibitor

DRUG4 trials

Sponsors

Alimentiv Inc., Zhejiang Provincial People's Hospital, Chao Ji, Peking Union Medical College Hospital

Conditions

AbataceptBlau SyndromeBullous PemphigoidCorticosteroidsJanus Kinase InhibitorRheumatoid ArthritisTreatment ComplianceUlcerative Colitis

Phase 3

Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Zhejiang Provincial People's HospitalAbatacept, Rheumatoid Arthritis, Treatment Compliance

Start: 2022-09-30End: 2024-06-30Target: 90Updated: 2022-09-23

Phase 4

Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome

Enrolling by invitationNCT06660329

Peking Union Medical College HospitalBlau Syndrome

Start: 2024-10-01End: 2028-10-01Target: 30Updated: 2024-10-28

Unknown Phase

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis

TerminatedNCT04576000

Alimentiv Inc.Ulcerative Colitis

Start: 2020-08-25End: 2021-12-02Updated: 2022-01-04

JAK Inhibitors' Efficacy in Bullous Pemphigoid

CompletedNCT06561256

Chao JiBullous Pemphigoid, Corticosteroids, Janus Kinase Inhibitor

Start: 2022-01-01End: 2024-07-31Updated: 2024-09-05